PHASE 1 SAFETY OUTCOMES OF MESENCHYMAL STROMAL STEM CELL THERAPY IN PATEINTS WITH LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME

被引：1
|
作者：
Cirillo, M. [1 ,2 ]
Carnley, B. [1 ,2 ]
Tan, P. [1 ]
Tan, D. [2 ]
Sturm, M. [2 ,3 ]
机构：
[1] Royal Perth Hosp, Haematol, Perth, WA, Australia
[2] Royal Perth Hosp, Cell & Tissue Therapies, Perth, WA, Australia
[3] Royal Perth Hosp, Perth, WA, Australia
来源：
CYTOTHERAPY | 2018年 / 20卷 / 05期
关键词：
D O I：
10.1016/j.jcyt.2018.02.078
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
80
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [21] A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
    Raza, Azra
    Galili, Naomi
    Smith, Scott E.
    Godwin, John
    Boccia, Ralph V.
    Myint, Han
    Mahadevan, Daruka
    Mulford, Deborah
    Rarick, Mark
    Brown, Gail L.
    Schaar, Dale
    Faderl, Stefan
    Komrokji, Rami S.
    List, Alan F.
    Sekeres, Mikkael
    [J]. CANCER, 2012, 118 (08) : 2138 - 2147
  • [22] Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome
    Dimicoli, Sophie
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Estrov, Zeev
    Yang, Hui
    Kelly, Mary
    Pierce, Sherry
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 127 - 129
  • [23] Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"
    Sebert, Marie
    Chaffaut, Cendrine
    Thepot, Sylvain
    Orvain, Corentin
    Cluzeau, Thomas
    Loschi, Michael
    Peterlin, Pierre
    Chevallier, Patrice
    d'Aveni, Maud
    Rubio, Marie-Therese
    Rauzy, Odile Beyne
    Huynh, Anne
    Charbonnier, Amandine
    Fegueux, Nathalie
    Fossard, Gaelle
    N'guyen-Quoc, Stephanie
    Park, Sophie
    Sapena, Rosa
    Chermat, Fatiha
    Ades, Lionel
    Chevret, Sylvie
    Fenaux, Pierre
    Robin, Marie
    [J]. BLOOD, 2021, 138 : 1842 - +
  • [24] Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Xiao, Lianchun
    Najla, Al Ali
    Mishra, Asmita
    Padron, Eric
    Lancet, Jeffrey E.
    Bryan, Jeffery
    Prescott, Hillary
    Steensma, David P.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    List, Alan
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    [J]. BLOOD, 2013, 122 (21)
  • [25] Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation
    Abaza, Yasmin
    Hidalgo-Lopez, Juliana E.
    Verstovsek, Srdan
    Jabbour, Elias
    Ravandi, Farhad
    Borthakur, Gautam
    Estrov, Zeev
    Alvarado, Yesid
    Burger, Jan
    Schneider, Heather
    Soltysiak, Kelly A.
    Wei, Yue
    Kantarjian, Hagop M.
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    [J]. LEUKEMIA RESEARCH, 2018, 73 : 78 - 85
  • [26] 5-AZACYTIDINE FOR THE TREATMENT OF LOW/INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 63 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM
    Musto, P.
    Maurillo, L.
    Spagnoli, A.
    Gozzini, A.
    Rivellini, F.
    Tatarelli, C.
    Lunghi, M.
    Fili, C.
    Orciuolo, E.
    Ciuffreda, L.
    Vigna, E.
    Della Cioppa, P.
    Ferrero, D.
    Palmieri, S.
    Palumbo, G.
    Di Renzo, N.
    Oliva, E.
    Sanpaolo, G.
    Pastore, D.
    Tonso, A.
    Santagostino, A.
    Villani, O.
    D'Auria, F.
    D'Arco, A.
    Gaidano, G.
    Galimberti, S.
    Russo, D.
    Venditti, A.
    Aloe-Spiriti, M. A.
    Leone, G.
    Santini, V.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 368 - 368
  • [27] ARCADE (20090160): A randomized controlled trial of darbepoetin alpha in anemic patients with low or intermediate-1 risk myelodysplastic syndrome (MDS)
    Gasal, E.
    Pan, C.
    Tankersley, C.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S166 - S167
  • [28] Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.
    Jabbour, Elias J.
    Daver, Naval G.
    Dong, Tina
    Kadia, Tapan M.
    O'Brien, Susan
    Cortes, Jorge E.
    Ravandi, Farhad
    Pemmaraju, Naveen
    Ghanem, Hady
    Faderl, Stefan
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2012, 120 (21)
  • [29] Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Estrov, Zeev
    Godley, Lucy
    Gabrail, Nashat Y.
    Berdeja, Jesus G.
    Nadeem, Ahmed
    Stein, Karen
    Noble, Yvonne
    Kassalow, Laurent
    Kantarjian, Hagop M.
    [J]. BLOOD, 2011, 118 (21) : 1628 - 1629
  • [30] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Goede, Jeroen Simon
    Guerci-Bresler, Agnes
    Delforge, Michel
    Oliva, Esther Natalie
    Mayer, Jiri
    Badre, Sejal
    Mehta, Bhakti
    Brandao, Cisio De Oliveira
    [J]. BLOOD, 2017, 130
12345